Anticoagulation Strategies in Non-Critically Ill Patients with Covid-19

NEJM Evid. 2023 Feb;2(2):EVIDoa2200293. doi: 10.1056/EVIDoa2200293. Epub 2022 Dec 10.

Abstract

Anticoagulation in Non-Critically Ill Covid-19 PatientsMcQuilten et al. conducted a randomized clinical trial comparing low-dose, intermediate-dose, low-dose plus aspirin, and therapeutic-dose anticoagulation in patients with Covid-19 of diverse ethnicities in high-, low-, and middle-income countries.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Anticoagulants / pharmacology
  • Aspirin / pharmacology
  • Blood Coagulation
  • COVID-19*
  • Humans

Substances

  • Anticoagulants
  • Aspirin